Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this... see more

TSX:MSCL - Post Discussion

Satellos Bioscience Inc > Webinar w $MSCL CEO Frank Gleeson - Tue Oct 18 @ 1PM ET
View:
Post by bmreed on Oct 14, 2022 2:06pm

Webinar w $MSCL CEO Frank Gleeson - Tue Oct 18 @ 1PM ET

Webinar - Satellos Bioscience Inc. $MSCL w/ CEO Frank Gleeson

Tue, October 18 at 1pm ET / 10am PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/5316655964074/WN_d6giQ6_bRjKdAPMljZUuJQ

Comment by G1945V on Oct 18, 2022 1:59pm
I just caught the last 10 minutes. Was anything new said outside of elaborating on the prospectus? Will a replay be available? TIA G1945V
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities